FDA Approves Labeling for RS, ANDA 202682

The FDA has posted approved labeling for RS, associated with Abbreviated New Drug Application (ANDA) 202682. This action signifies the finalization of labeling requirements for this specific drug product.

Drug manufacturers with products affected by this labeling update should ensure their compliance with the approved specifications. No immediate compliance deadline or penalty information is provided, indicating this is a standard approval notification.